EASD 2019 — Liraglutide reduces insulin dose in newly diagnosed T1D


  • Brandon May
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Once-daily liraglutide, when added to insulin therapy, was associated with preservation of postprandial insulin secretion and reduction in total insulin dose in patients with newly diagnosed type 1 diabetes (T1D). 

Why this matters

  • Patients with newly diagnosed T1D produce little insulin.

Key results

  • The mean diabetes duration was 4.4±1.2 weeks, and fasting C-peptide was 359±226 pM.
  • At 52 weeks, liraglutide was associated with sustained stimulated C-peptide secretion and a greater reduction in insulin dose vs placebo (total insulin dose: 18 vs 32 IU; P<.001>
  • There was no difference between the liraglutide and placebo groups in terms of stimulated C-peptide levels and total insulin dose at 58 weeks.
  • The researchers observed no difference between the groups in terms of HbA1c (P=.35) or body weight (P=.87) at end of treatment.

Study design

  • Adult patients with T1D who were diagnosed within 6 weeks of screening were enrolled in the 52-week trial.
  • Participants were randomly assigned to once-daily liraglutide 1.8 mg (n=31) in addition to insulin therapy or placebo (n=32) plus insulin.
  • Assessment of C-peptide response was conducted after a liquid mixed meal test consisting of 41 g of carbohydrate.
  • Primary endpoint was area under the C-peptide curve or area under the curve (AUC) of C-peptide/AUC p-glucose after the liquid meal test.
  • Funding: Novo Nordisk.

Limitations

  • Small sample size.